Pimecrolimus
| Evidence Level: L2 | Predicted Indications: 3 |
Table of Contents
Pimecrolimus: Seborrheic dermatitis
One-Sentence Summary
Pimecrolimus is a topical calcineurin inhibitor, originally used to treat atopic dermatitis (eczema). The TxGNN model predicts it may be effective for seborrheic dermatitis, supported by 1 Phase 2 clinical trial and 2 systematic reviews of randomised controlled trials, along with several open-label studies and narrative reviews.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Seborrheic dermatitis |
| TxGNN Prediction Score | 0.9973 |
| Evidence Level | L2 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data were not available in the data compiled for this report. Published reviews describe pimecrolimus as a topical calcineurin inhibitor. It blocks T-cell activation, reduces production of interleukin-2 (IL-2), IL-4, interferon-gamma and tumour necrosis factor-alpha, and inhibits mast cell degranulation.
Seborrheic dermatitis is a chronic, relapsing inflammatory skin condition. It involves an inflammatory response to Malassezia yeast in sebum-rich areas such as the face and scalp. Atopic dermatitis and seborrheic dermatitis are both inflammatory dermatoses, so a non-steroidal anti-inflammatory agent is mechanistically plausible. This also matters because long-term topical corticosteroid use on the face carries well-known adverse effects.
The clinical evidence is strongest for facial disease. Two systematic reviews of randomised trials report that pimecrolimus 1% cream is well tolerated and effective, with efficacy comparable to the comparators examined. No Phase 3 trial in this indication was identified, which limits confidence.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00403559 | Phase 2 | Completed | 113 | Four-week randomised, double-blind, active-comparator exploratory study of Elidel (pimecrolimus) in seborrheic dermatitis |
No ANZCTR identifiers were found in the data compiled for this report.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22142161 | 2012 | Systematic review of RCTs | Expert Rev Clin Pharmacol | Pimecrolimus 1% cream appears well tolerated and effective for seborrheic dermatitis versus corticosteroids, antimycotics, placebo or no intervention |
| 36072203 | 2022 | Systematic review of RCTs | Cureus | Critical review of the efficacy and safety of pimecrolimus in facial seborrheic dermatitis |
| 27804089 | 2017 | Systematic review | Am J Clin Dermatol | Reviews topical treatment of facial seborrheic dermatitis (antifungals, keratolytics, corticosteroids) |
| 31053034 | 2019 | Review | J Cutan Med Surg | Reviews off-label uses of topical pimecrolimus, focusing on published RCTs |
| 19222250 | 2009 | Review | Am J Clin Dermatol | Topical calcineurin inhibitors are a safer alternative to corticosteroids for seborrheic dermatitis |
| 20000875 | 2010 | Open-label study | Am J Clin Dermatol | Pimecrolimus 1% cream effective and well tolerated in resistant facial seborrheic dermatitis |
| 17982237 | 2007 | Open-label study | J Korean Med Sci | Twenty Korean patients applied pimecrolimus 1% cream for 4 weeks to facial seborrheic dermatitis; efficacy and tolerability assessed |
| 16033622 | 2005 | Review | Int J Clin Pract | Describes pimecrolimus’s selective action on T cells and mast cells, and its potential beyond atopic dermatitis |
| 17020422 | 2006 | Review | Expert Opin Pharmacother | Topical pimecrolimus has potential in inflammatory skin diseases other than atopic dermatitis |
| 19213227 | 2009 | Review | J Drugs Dermatol | Overview of facial seborrheic dermatitis and its therapeutic options |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 8802G | Elidel | Cream 10 mg per g, 15 g (topical) | Not stated in the data compiled for this report |
Safety Considerations
- Contraindications flagged in the knowledge graph (these come from drug-disease network data, not product label text): common wart, epidermodysplasia verruciformis, anogenital human papillomavirus infection, herpes simplex infection, herpes simplex dermatitis, herpes zoster, chickenpox, infectious mononucleosis, chronic Epstein-Barr virus infection syndrome, lymphatic system disease, Netherton syndrome, and ichthyosis linearis circumflexa.
- Malignancy warning: the literature describes a boxed warning regarding malignancy (including lymphoma and skin cancer) for topical pimecrolimus. A 2023 systematic review and meta-analysis (PMID 36370744) examined cancer risk with topical calcineurin inhibitors, and a 10-year paediatric registry (NCT00568997) is ongoing.
- Masking of infection: reviews note that topical immunomodulators can alter the appearance of fungal skin infections (tinea incognito), which can delay diagnosis.
- Drug interactions: 100 potential interactions were recorded, all with an unclassified severity level. Examples include triamcinolone, prednisone, hydrocortisone, budesonide, omeprazole, pantoprazole, simvastatin, metformin and doxycycline. The clinical significance of these is not established in the data.
Product Information warnings and contraindications were not available. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 2 active-comparator trial and two systematic reviews of RCTs support efficacy in facial seborrheic dermatitis, and pimecrolimus is already marketed in Australia as a topical cream. However, there is no Phase 3 trial in this indication, and the boxed malignancy warning limits the strength of the recommendation.
To proceed, the following is needed:
- The TGA-approved Product Information, to confirm warnings, contraindications and the registered indication
- Detailed mechanism-of-action data (for example from DrugBank)
- Confirmation of the registered indication and age restrictions of the Australian Elidel product
- A defined use scope (for example facial disease, short-term or intermittent use, second-line after other options) with a monitoring plan for malignancy and infection risk
- Ideally, an adequately powered Phase 3 trial or a review of the full results of NCT00403559
Other predictions in the dataset (for reference only): “Exanthem” (rank 3) is supported only by small, heterogeneous pilot trials (including oral and vulvar lichen disorders and EGFR-inhibitor rash) and should be treated as a research question. Predictions ranked 4 to 10 have no trials or literature and should be held.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.